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Accurately staging liver fibrosis is crucial for treatment
decisions and prognostication in HIV-infected patients
with liver disease. Liver biopsy is currently the gold stand-
ard for determining the stage of liver fibrosis. There are
risks associated with liver biopsy; therefore, surrogate
markers to predict the severity of disease would be useful.
Available fibrosis marker panels have acceptable perform-
ance for identifying significant fibrosis and cirrhosis in
HIV/HCV-coinfected patients but are not yet adequate to
replace liver biopsy. Additional studies are necessary to
identify the optimal measure. Transient elastometry (TE)
is accurate for detecting significant liver fibrosis and cir-
rhosis in hepatitis C virus (HCV)-monoinfected patients.
However, this procedure has been insufficiently validated
in patients with human immunodeficiency virus (HIV)
and HCV co-infection. The diagnostic accuracy of TE is
high for detecting cirrhosis and good for diagnosis of sig-
nificant liver fibrosis. However, the performance of TE is
low for discriminating mild fibrosis from significant liver
fibrosis, which might limit the applicability of this tech-
nique in clinical practice.
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